Fenoldopam mesylate for treating psoriasis: A new indication for an old drug

Sindhu Doppalapudi; Anjali Jain; Wahid Khan; Abraham J. Domb

doi:10.1016/j.ijpharm.2019.118726

Fenoldopam mesylate for treating psoriasis: A new indication for an old drug

Sindhu Doppalapudi, Anjali Jain, Wahid Khan, Abraham J. Domb

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Fenoldopam, a highly selective dopamine receptor agonist, is available in clinics as Corlopam™ i.v. for the management of severe hypertension. Recent reports demonstrate its anti-proliferative activity in vitro in a dose dependent manner. However, stability issues of the drug due to its susceptibility to oxidation, pH sensitivity, poor transdermal flux, and the barrier properties of skin present challenges to develop a topical formulation of fenoldopam. The aim of the present study is to suggest a stable topical formulation of fenoldopam for the treatment of psoriasis. Water washable ointment and glycerin-based carbopol anhydrous gel of fenoldopam intended for topical delivery were prepared and evaluated in vitro and in vivo. Results from pH dependent stability studies suggest the necessity to maintain acidic pH in final formulations. The presence of an acidic adjuster in ointment and unneutralised carbopol dispersion of anhydrous gel maintain the desired acidic environment in the formulations. Stability studies of prepared formulations performed for 90 days indicate that the drug remains stable in formulations. In vivo studies demonstrate the applicability of the formulations for better skin penetration, skin compliance, and photosafety. Efficacy studies using an imiquimod induced psoriasis model confirm the promising application of developed fenoldopam topical formulations for psoriasis.

Original language	English
Article number	118726
Journal	International Journal of Pharmaceutics
Volume	573
DOIs	https://doi.org/10.1016/j.ijpharm.2019.118726
State	Published - 5 Jan 2020
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2019 Elsevier B.V.

Funding

The authors are thankful to Mr. Nagavendra Kommineni for preparation of manuscript. Authors also thankful to Director, NIPER-Hyderabad for providing required facilities, support, and encouragement throughout the project. This work was supported by a grant (FG 002) from YISSUM, The Hebrew University of Jerusalem. The authors are thankful to Mr. Nagavendra Kommineni for preparation of manuscript. Authors also thankful to Director, NIPER-Hyderabad for providing required facilities, support, and encouragement throughout the project. This work was supported by a grant ( FG 002 ) from YISSUM, The Hebrew University of Jerusalem .

Funders	Funder number
NIPER-Hyderabad	FG 002
YISSUM
Hebrew University of Jerusalem

Keywords

Fenoldopam
Imiquimod induced psoriasis model
Psoriasis
Skin penetration
Stability
Topical delivery

Access to Document

10.1016/j.ijpharm.2019.118726

Cite this

@article{35bfcf91c50b44b3b4153099b965fed5,

title = "Fenoldopam mesylate for treating psoriasis: A new indication for an old drug",

abstract = "Fenoldopam, a highly selective dopamine receptor agonist, is available in clinics as Corlopam{\texttrademark} i.v. for the management of severe hypertension. Recent reports demonstrate its anti-proliferative activity in vitro in a dose dependent manner. However, stability issues of the drug due to its susceptibility to oxidation, pH sensitivity, poor transdermal flux, and the barrier properties of skin present challenges to develop a topical formulation of fenoldopam. The aim of the present study is to suggest a stable topical formulation of fenoldopam for the treatment of psoriasis. Water washable ointment and glycerin-based carbopol anhydrous gel of fenoldopam intended for topical delivery were prepared and evaluated in vitro and in vivo. Results from pH dependent stability studies suggest the necessity to maintain acidic pH in final formulations. The presence of an acidic adjuster in ointment and unneutralised carbopol dispersion of anhydrous gel maintain the desired acidic environment in the formulations. Stability studies of prepared formulations performed for 90 days indicate that the drug remains stable in formulations. In vivo studies demonstrate the applicability of the formulations for better skin penetration, skin compliance, and photosafety. Efficacy studies using an imiquimod induced psoriasis model confirm the promising application of developed fenoldopam topical formulations for psoriasis.",

keywords = "Fenoldopam, Imiquimod induced psoriasis model, Psoriasis, Skin penetration, Stability, Topical delivery",

author = "Sindhu Doppalapudi and Anjali Jain and Wahid Khan and Domb, {Abraham J.}",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2020",

month = jan,

day = "5",

doi = "10.1016/j.ijpharm.2019.118726",

language = "אנגלית",

volume = "573",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Fenoldopam mesylate for treating psoriasis

T2 - A new indication for an old drug

AU - Doppalapudi, Sindhu

AU - Jain, Anjali

AU - Khan, Wahid

AU - Domb, Abraham J.

PY - 2020/1/5

Y1 - 2020/1/5

N2 - Fenoldopam, a highly selective dopamine receptor agonist, is available in clinics as Corlopam™ i.v. for the management of severe hypertension. Recent reports demonstrate its anti-proliferative activity in vitro in a dose dependent manner. However, stability issues of the drug due to its susceptibility to oxidation, pH sensitivity, poor transdermal flux, and the barrier properties of skin present challenges to develop a topical formulation of fenoldopam. The aim of the present study is to suggest a stable topical formulation of fenoldopam for the treatment of psoriasis. Water washable ointment and glycerin-based carbopol anhydrous gel of fenoldopam intended for topical delivery were prepared and evaluated in vitro and in vivo. Results from pH dependent stability studies suggest the necessity to maintain acidic pH in final formulations. The presence of an acidic adjuster in ointment and unneutralised carbopol dispersion of anhydrous gel maintain the desired acidic environment in the formulations. Stability studies of prepared formulations performed for 90 days indicate that the drug remains stable in formulations. In vivo studies demonstrate the applicability of the formulations for better skin penetration, skin compliance, and photosafety. Efficacy studies using an imiquimod induced psoriasis model confirm the promising application of developed fenoldopam topical formulations for psoriasis.

AB - Fenoldopam, a highly selective dopamine receptor agonist, is available in clinics as Corlopam™ i.v. for the management of severe hypertension. Recent reports demonstrate its anti-proliferative activity in vitro in a dose dependent manner. However, stability issues of the drug due to its susceptibility to oxidation, pH sensitivity, poor transdermal flux, and the barrier properties of skin present challenges to develop a topical formulation of fenoldopam. The aim of the present study is to suggest a stable topical formulation of fenoldopam for the treatment of psoriasis. Water washable ointment and glycerin-based carbopol anhydrous gel of fenoldopam intended for topical delivery were prepared and evaluated in vitro and in vivo. Results from pH dependent stability studies suggest the necessity to maintain acidic pH in final formulations. The presence of an acidic adjuster in ointment and unneutralised carbopol dispersion of anhydrous gel maintain the desired acidic environment in the formulations. Stability studies of prepared formulations performed for 90 days indicate that the drug remains stable in formulations. In vivo studies demonstrate the applicability of the formulations for better skin penetration, skin compliance, and photosafety. Efficacy studies using an imiquimod induced psoriasis model confirm the promising application of developed fenoldopam topical formulations for psoriasis.

KW - Fenoldopam

KW - Imiquimod induced psoriasis model

KW - Psoriasis

KW - Skin penetration

KW - Stability

KW - Topical delivery

UR - http://www.scopus.com/inward/record.url?scp=85076202758&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2019.118726

DO - 10.1016/j.ijpharm.2019.118726

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 31715365

AN - SCOPUS:85076202758

SN - 0378-5173

VL - 573

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

M1 - 118726

ER -

Fenoldopam mesylate for treating psoriasis: A new indication for an old drug

Abstract

Bibliographical note

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this